U.S., Dec. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07271121) titled 'Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL' on Nov. 24.
Brief Summary: This is a Prospective Single Center, open label, Non-randomized, Single Arm, Single Dose, Phase II Clinical Trial. Adult patients >18-year-old with CD19+ Non-Hodgkin lymphoma are eligible for the study if they meet eligibility criteria. Patients will receive a fresh single dose of MB-CART-19.1 and will be followed for 12 months and evaluated for efficacy and safety.
Study Start Date: Feb. 12
Study Type: INTERVENTIONAL
Condition:
Non-Hodgkin Lymphoma Refractory/ Relapsed
Intervention:
OTHER: MB-CART-19.1
The l...